Acute exacerbation of chronic obstructive pulmonary disease: cardiovascular links

Cheryl R Laratta, Stephan van Eeden, Cheryl R Laratta, Stephan van Eeden

Abstract

Chronic obstructive pulmonary disease (COPD) is a chronic, progressive lung disease resulting from exposure to cigarette smoke, noxious gases, particulate matter, and air pollutants. COPD is exacerbated by acute inflammatory insults such as lung infections (viral and bacterial) and air pollutants which further accelerate the steady decline in lung function. The chronic inflammatory process in the lung contributes to the extrapulmonary manifestations of COPD which are predominantly cardiovascular in nature. Here we review the significant burden of cardiovascular disease in COPD and discuss the clinical and pathological links between acute exacerbations of COPD and cardiovascular disease.

Figures

Figure 1
Figure 1
Presence of an electrocardiogram (ECG) abnormality and length of stay (LOS) of subjects admitted with an AECOPD to St. Paul's Hospital or Mount St. Joseph's Hospital between 2007 and 2008. The presence of ECG abnormalities did not influence LOS (11.7 ± 1.4 versus 13.2 ± 1.5, (a) P = NS). Subjects with ischemic changes on ECG had a longer LOS (11.2 ± 1.0 versus 16.6 ± 3.0, (b) P = 0.031).
Figure 2
Figure 2
Acute inflammatory events in the lungs provoke a cascade of systemic inflammation that starts in the lung, with hematologic spread to other organs, activating the systemic inflammatory response, and thereby promoting the development of atherosclerosis and vascular events.
Figure 3
Figure 3
AECOPD is associated with an acute lung injury initiating the local and systemic inflammatory pathways that cause endothelial injury and vascular dysfunction, a prothrombotic environment, and instability in vascular plaques that may predispose to coronary and cerebrovascular events.

References

    1. Hogg JC, Timens W. The pathology of chronic obstructive pulmonary disease. Annual Review of Pathology. 2009;4:435–459.
    1. Zvezdin B, Milutinov S, Kojicic M, et al. A postmortem analysis of major causes of early death in patients hospitalized with COPD exacerbation. Chest. 2009;136(2):376–380.
    1. Suissa S, Dell'Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012;67(11):957–963.
    1. Finkelstein J, Cha E, Scharf SM. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity. International Journal of Chronic Obstructive Pulmonary Disease. 2009;4:337–349.
    1. Cui H, Miao D-M, Wei Z-M, et al. Prevalence of cardiovascular disease in subjects hospitalized due to chronic obstructive pulmonary disease in Beijing from 2000 to 2010. Journal of Geriatric Cardiology. 2012;9(1):5–10.
    1. Sidney S, Sorel M, Quesenberry CP, Jr., DeLuise C, Lanes S, Eisner MD. COPD and incident cardiovascular disease hospitalizations and mortality: kaiser permanente medical care program. Chest. 2005;128(4):2068–2075.
    1. Schunemann HJ, Dorn J, Grant BJB, Winkelstein JW, Trevisan M. Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. Chest. 2000;118(3):656–664.
    1. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Annals of Internal Medicine. 2005;142(4):233–239.
    1. Sin DD, Wu L, Man SFP. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest. 2005;127(6):1952–1959.
    1. Ford ES, Wheaton AG, Mannino DM, Presley-Cantrell L, Li C, Croft JB. Elevated cardiovascular risk among adults with obstructive and restrictive airway functioning in the United States: a cross-sectional study of the National Health and Nutrition Examination Survey from 2007–2010. Respiratory Research. 2012;13, article 115
    1. Salisbury AC, Reid KJ, Spertus JA. Impact of chronic obstructive pulmonary disease on post-myocardial infarction outcomes. The American Journal of Cardiology. 2007;99(5):636–641.
    1. Lee TA, Pickard AS, Au DH, Bartle B, Weiss KB. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Annals of Internal Medicine. 2008;149(6):380–390.
    1. Mapel DW, Dedrick D, Davis K. Trends and cardiovascular co-morbidities of COPD patients in the veterans administration medical system, 1991–1999. Journal of Chronic Obstructive Pulmonary Disease. 2005;2(1):35–41.
    1. Macchia A, Rodriguez Moncalvo JJ, Kleinert M, et al. Unrecognised ventricular dysfunction in COPD. European Respiratory Journal. 2012;39(1):51–58.
    1. Hole DJ, Watt GCM, Davey-Smith G, Hart CL, Gillis CR, Hawthorne VM. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. British Medical Journal. 1996;313(7059):711–716.
    1. Ekberg-Aronsson M, Löfdahl K, Nilsson J-Å, Löfdahl C-G, Nilsson PM. Hospital admission rates among men and women with symptoms of chronic bronchitis and airflow limitation corresponding to the gold stages of chronic obstructive pulmonary disease—a population-based study. Respiratory Medicine. 2008;102(1):109–120.
    1. Boudestein LCM, Rutten FH, Cramer MJ, Lammers JWJ, Hoes AW. The impact of concurrent heart failure on prognosis in patients with chronic obstructive pulmonary disease. European Journal of Heart Failure. 2009;11(12):1182–1188.
    1. Flu W-J, van Gestel YRBM, van Kuijk J-P, et al. Co-existence of COPD and left ventricular dysfunction in vascular surgery patients. Respiratory Medicine. 2010;104(5):690–696.
    1. Jousilahti P, Vartiainen E, Tuomilehto J, Puska P. Symptoms of chronic bronchitis and the risk of coronary disease. The Lancet. 1996;348(9027):567–572.
    1. Bursi F, Vassallo R, Weston SA, Killian JM, Roger VL. Chronic obstructive pulmonary disease after myocardial infarction in the community. American Heart Journal. 2010;160(1):95–101.
    1. Hawkins NM, Huang Z, Pieper KS, et al. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the valsartan in acute myocardial infarction trial (VALIANT) European Journal of Heart Failure. 2009;11(3):292–298.
    1. Samuels LE, Kaufman MS, Morris RJ, Promisloff R, Brockman SK. Coronary artery bypass grafting in patients with COPD. Chest. 1998;113(4):878–882.
    1. Angouras DC, Anagnostopoulos CE, Chamogeorgakis TP, et al. Postoperative and long-term outcome of patients with chronic obstructive pulmonary disease undergoing coronary artery bypass grafting. The Annals of Thoracic Surgery. 2010;89(4):1112–1118.
    1. Leavitt BJ, Ross CS, Spence B, et al. Long-term survival of patients with chronic obstructive pulmonary disease undergoing coronary artery bypass surgery. Circulation. 2006;114(1):I430–I434.
    1. Egred M, Shaw S, Mohammad B, Waitt P, Rodrigues E. Under-use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease. QJM. 2005;98(7):493–497.
    1. Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJV. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. European Journal of Heart Failure. 2009;11(2):130–139.
    1. O’Donnell CJ, Elosua R. Cardiovascular risk factors. Insights from framingham heart study. Revista Espanola de Cardiologia. 2008;61(3):299–310.
    1. Wilson PWF, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837–1847.
    1. Terzano C, Conti V, Di Stefano F, et al. Comorbidity, hospitalization, and mortality in COPD: results from a longitudinal study. Lung. 2010;188(4):321–329.
    1. Chandy D, Aronow WS, Banach M. Current perspectives on treatment of hypertensive patients with chronic obstructive pulmonary disease. Journal of Integrated Blood Pressure Control. 2013;6:101–109.
    1. Marquis K, Maltais F, Duguay V, et al. The metabolic syndrome in patients with chronic obstructive pulmonary disease. Journal of Cardiopulmonary Rehabilitation. 2005;25(4):226–232.
    1. Diez-Manglano J, Barquero-Romero J, Almagro P, et al. COPD patients with and without metabolic syndrome: clinical and functional differences. Internal Emergency Medicine. 2013
    1. Sabino PG, Silva BM, Brunetto AF. Nutritional status is related to fat-free mass, exercise capacity and inspiratory strength in severe chronic obstructive pulmonary disease patients. The Clinics. 2010;65(6):599–605.
    1. Cao C, Wang R, Wang J, Bunjhoo H, Xu Y, Xiong W. Body mass index and mortality in chronic obstructive pulmonary disease: a meta-analysis. PLoS ONE. 2012;7:1–8.
    1. Gudmundsson G, Ulrik CS, Gislason T, et al. Long-term survival in patients hospitalized for chronic obstructive pulmonary disease: a prospective observational study in the Nordic countries. International Journal of Chronic Obstructive Pulmonary Disease. 2012;7:571–576.
    1. Yuji H, Toshiyuki Y, Noritsugu H, et al. Clinical and inflammatory factors associated with body mass index in elderly patients with chronic obstructive pulmonary disease. Geriatrics and Gerontology International. 2011;11(1):32–38.
    1. Man SFP, Connett JE, Anthonisen NR, Wise RA, Tashkin DP, Sin DD. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax. 2006;61(10):849–853.
    1. Man SFP, van Eeden S, Sin DD. Vascular risk in chronic obstructive pulmonary disease: role of inflammation and other mediators. Canadian Journal of Cardiology. 2012;28(6):653–661.
    1. Mills NL, Miller JJ, Anand A, et al. Increased arterial stiffness in patients with chronic obstructive pulmonary disease: a mechanism for increased cardiovascular risk. Thorax. 2008;63(4):306–311.
    1. Moro L, Pedone C, Scarlata S, Malafarina V, Fimognari F, Antonelli-Incalzi R. Endothelial dysfunction in chronic obstructive pulmonary disease. Angiology. 2008;59(3):357–364.
    1. Eickhoff P, Valipour A, Kiss D, et al. Determinants of systemic vascular function in patients with stable chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine. 2008;178(12):1211–1218.
    1. Blum A, Simsolo C, Sirchan R. Vascular responsiveness in patients with Chronic Obstructive Pulmonary Disease (COPD) European Journal of Internal Medicine. 2013
    1. Maclay JD, McAllister DA, Mills NL, et al. Vascular dysfunction in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine. 2009;180(6):513–520.
    1. van Gestel YRBM, Flu W-J, van Kuijk J-P, et al. Association of COPD with carotid wall intima-media thickness in vascular surgery patients. Respiratory Medicine. 2010;104(5):712–716.
    1. Vivodtzev I, Minet C, Tamisier R, et al. Arterial stiffness by pulse wave velocity in COPD: reliability and reproducibility. European Respiratory Journal. 2013;42(4):1140–1142.
    1. Cinarka H, Kayhan S, Gumus A, et al. Arterial stiffness measured by carotid femoral pulse wave velocity is associated with disease severity in chronic obstructive pulmonary disease. Respiratory Care. 2013
    1. Bolton CE, Cockcroft JR, Sabit R, et al. Lung function in mid-life compared with later life is a stronger predictor of arterial stiffness in men: the caerphilly prospective study. International Journal of Epidemiology. 2009;38(3):867–876.
    1. Sakuragi S, Abhayaratna WP. Arterial stiffness: methods of measurement, physiologic determinants and prediction of cardiovascular outcomes. International Journal of Cardiology. 2010;138(2):112–118.
    1. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness. A systematic review and meta-analysis. Journal of the American College of Cardiology. 2010;55(13):1318–1327.
    1. Stone IS, John L, Petersen SE, Barnes NC. Reproducibility of arterial stiffness and wave reflections in chronic obstructive pulmonary disease: the contribution of lung hyperinflation and a comparison of techniques. Respiratory Medicine. 2013;107(11):1700–1708.
    1. Marchetti N, Ciccolella DE, Jacobs MR, et al. Hospitalized acute exacerbation of COPD impairs flow and nitroglycerin-mediated peripheral vascular dilation. Journal of Chronic Obstructive Pulmonary Disease. 2011;8(2):60–65.
    1. Clarenbach CF, Senn O, Sievi NA, et al. Determinants of endothelial function in patients with COPD. European Respiratory Journal. 2013;42(5):1194–1204.
    1. Tamagawa E, van Eeden SF. Impaired lung function and risk for stroke: role of the systemic inflammation response? Chest. 2006;130(6):1631–1633.
    1. Feary JR, Rodrigues LC, Smith CJ, Hubbard RB, Gibson JE. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax. 2010;65(11):956–962.
    1. Leuchte HH, Baumgartner RA, El Nounou M, et al. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. American Journal of Respiratory and Critical Care Medicine. 2006;173(7):744–750.
    1. Cuttica MJ, Kalhan R, Shlobin OA, et al. Categorization and impact of pulmonary hypertension in patients with advanced COPD. Respiratory Medicine. 2010;104(12):1877–1882.
    1. Minai OA, Chaouat A, Adnot S. Pulmonary hypertension in COPD: epidemiology, significance, and management: pulmonary vascular disease: the global perspective. Chest. 2010;137(6, supplement 1):39S–51S.
    1. Wright JL, Lawson L, Pare PD, et al. The structure and function of the pulmonary vasculature in mild chronic obstructive pulmonary disease. The effect of oxygen and exercise. The American Review of Respiratory Disease. 1983;128(4):702–707.
    1. Santos S, Peinado VI, Ramírez J, et al. Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD. European Respiratory Journal. 2002;19(4):632–638.
    1. Kessler R, Faller M, Weitzenblum E, et al. ‘Natural history’ of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease. American Journal of Respiratory and Critical Care Medicine. 2001;164(2):219–224.
    1. Chaouat A, Bugnet A-S, Kadaoui N, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine. 2005;172(2):189–194.
    1. Sincer I, Zorlu A, Yilmaz MB, et al. Relationship between red cell distribution width and right ventricular dysfunction in patients with chronic obstructive pulmonary disease. Heart and Lung. 2012;41(3):238–243.
    1. Vizza CD, Lynch JP, Ochoa LL, Richardson G, Trulock EP. Right and left ventricular dysfunction in patients with severe pulmonary disease. Chest. 1998;113(3):576–583.
    1. Stone AC, Machan JT, Mazer J, Casserly B, Klinger JR. Echocardiographic evidence of pulmonary hypertension is associated with increased 1-year mortality in patients admitted with chronic obstructive pulmonary disease. Lung. 2011;189(3):207–212.
    1. de Miguel Diez J, Chancafe Morgan J, Jimenez Garcia R. The association between COPD and heart failure risk: a review. International Journal of Chronic Obstructive Pulmonary Disease. 2013;8:305–312.
    1. Soriano JB, Rigo F, Guerrero D, et al. High prevalence of undiagnosed airflow limitation in patients with cardiovascular disease. Chest. 2010;137(2):333–340.
    1. Kwon B-J, Kim D-B, Jang S-W, et al. Prognosis of heart failure patients with reduced and preserved ejection fraction and coexistent chronic obstructive pulmonary disease. European Journal of Heart Failure. 2010;12(12):1339–1344.
    1. McCullough PA, Hollander JE, Nowak RM, et al. Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department. Academic Emergency Medicine. 2003;10(3):198–204.
    1. Hudson LD, Kurt TL, Petty TL, Genton E. Arrhythmias associated with acute respiratory failure in patients with chronic airway obstruction. Chest. 1973;63(5):661–665.
    1. Engström G, Wollmer P, Hedblad B, Juul-Möller S, Valind S, Janzon L. Occurrence and prognostic significance of ventricular arrhythmia is related to pulmonary function: a study from “men born in 1914,” Malmö, Sweden. Circulation. 2001;103(25):3086–3091.
    1. Sekine Y, Kesler KA, Behnia M, Brooks-Brunn J, Sekine E, Brown JW. COPD may increase the incidence of refractory supraventricular arrhythmias following pulmonary resection for non-small cell lung cancer. Chest. 2001;120(6):1783–1790.
    1. Medina AM, Marteles MS, Sáiz EB, et al. Prognostic utility of NT-proBNP in acute exacerbations of chronic pulmonary diseases. European Journal of Internal Medicine. 2011;22(2):167–171.
    1. Steer J, Gibson J, Bourke SC. The DECAF score: predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease. Thorax. 2012;67(11):970–976.
    1. Buch P, Friberg J, Scharling H, Lange P, Prescott E. Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study. European Respiratory Journal. 2003;21(6):1012–1016.
    1. Stewart S, Hart CL, Hole DJ, McMurray JJV. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart. 2001;86(5):516–521.
    1. McCord J, Borzak S. Multifocal atrial tachycardia. Chest. 1998;113(1):203–209.
    1. Kothari SA, Apiyasawat S, Asad N, Spodick DH. Evidence supporting a new rate threshold for multifocal atrial tachycardia. Clinical Cardiology. 2005;28(12):561–563.
    1. Scher DL, Arsura EL. Multifocal atrial tachycardia: mechanisms, clinical correlates, and treatment. American Heart Journal. 1989;118(3):574–580.
    1. Patil SP, Krishnan JA, Lechtzin N, Diette GB. In-hospital mortality following acute exacerbations of chronic obstructive pulmonary disease. Archives of Internal Medicine. 2003;163(10):1180–1186.
    1. Soler-Cataluña JJ, Martínez-García MÁ, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60(11):925–931.
    1. Roberts CM, Lowe D, Bucknall CE, Ryland I, Kelly Y, Pearson MG. Clinical audit indicators of outcome following admission to hospital with acute exacerbation of chronic obstructive pulmonary disease. Thorax. 2002;57(2):137–141.
    1. Price LC, Lowe D, Hosker HSR, Anstey K, Pearson MG, Roberts CM. UK National COPD Audit 2003: impact of hospital resources and organisation of care on patient outcome following admission for acute COPD exacerbation. Thorax. 2006;61(10):837–842.
    1. Fruchter O, Yigla M. Cardiac troponin-I predicts long-term mortality in chronic obstructive pulmonary disease. Journal of Chronic Obstructive Pulmonary Disease. 2009;6(3):155–161.
    1. Steer J, Gibson GJ, Bourke SC. Predicting outcomes following hospitalization for acute exacerbations of COPD. QJM. 2010;103(11):817–829.
    1. Chang CL, Robinson SC, Mills GD, et al. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax. 2011;66(9):764–768.
    1. Kessler R, Faller M, Fourgaut G, Mennecier B, Weitzenblum E. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine. 1999;159(1):158–164.
    1. Marcun R, Sustic A, Brguljan PM, et al. Cardiac biomarkers predict outcome after hospitalisation for an acute exacerbation of chronic obstructive pulmonary disease. International Journal of Cardiology. 2012;161(3):156–159.
    1. McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA. Ascertainment of cause-specific mortality in COPD: operations of the TORCH clinical endpoint committee. Thorax. 2007;62(5):411–415.
    1. Brekke PH, Omland T, Smith P, Søyseth V. Underdiagnosis of myocardial infarction in COPD—Cardiac Infarction Injury Score (CIIS) in patients hospitalised for COPD exacerbation. Respiratory Medicine. 2008;102(9):1243–1247.
    1. Beghé B, Verduri A, Roca M, Fabbri LM. Exacerbation of respiratory symptoms in COPD patients may not be exacerbations of COPD. European Respiratory Journal. 2013;41(4):993–995.
    1. Garcia-Aymerich J, Farrero E, Félez MA, Izquierdo J, Marrades RM, Antó JM. Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. Thorax. 2003;58(2):100–105.
    1. Mannino DM, Davis KJ. Lung function decline and outcomes in an elderly population. Thorax. 2006;61(6):472–477.
    1. Mannino DM, Watt G, Hole D, et al. The natural history of chronic obstructive pulmonary disease. European Respiratory Journal. 2006;27(3):627–643.
    1. Wong AWM, Gan WQ, Burns J, Sin DD, van Eeden SF. Acute exacerbation of chronic obstructive pulmonary disease: influence of social factors in determining length of hospital stay and readmission rates. Canadian Respiratory Journal. 2008;15(7):361–364.
    1. Martins CS, Rodrigues MJO, Miranda VP, Nunes JPL. Prognostic value of cardiac troponin I in patients with COPD acute exacerbation. The Netherlands Journal of Medicine. 2009;67(10):341–349.
    1. Harvey MG, Hancox RJ. Elevation of cardiac troponins in exacerbation of chronic obstructive pulmonary disease. Emergency Medicine Australasia. 2004;16(3):212–215.
    1. Clayton TC, Thompson M, Meade TW. Recent respiratory infection and risk of cardiovascular disease: case-control study through a general practice database. European Heart Journal. 2008;29(1):96–103.
    1. Meier CR, Jick SS, Derby LE, Vasilakis C, Jick H. Acute respiratory-tract infections and risk of first-time acute myocardial infarction. The Lancet. 1998;351(9114):1467–1471.
    1. Corrales-Medina VF, Madjid M, Musher DM. Role of acute infection in triggering acute coronary syndromes. The Lancet Infectious Diseases. 2010;10(2):83–92.
    1. Huiart L, Ernst P, Ranouil X, Suissa S. Oral corticosteroid use and the risk of acute myocardial infarction in chronic obstructive pulmonary disease. Canadian Respiratory Journal. 2006;13(3):134–138.
    1. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. The New England Journal of Medicine. 2004;351(25):2611–2618.
    1. Nichol KL, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwane M. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. The New England Journal of Medicine. 2003;348(14):1322–1332.
    1. Siscovick DS, Raghunathan TE, Lin D, et al. Influenza vaccination and the risk of primary cardiac arrest. American Journal of Epidemiology. 2000;152(7):674–677.
    1. Warren-Gash C, Smeeth L, Hayward AC. Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: a systematic review. The Lancet Infectious Diseases. 2009;9(10):601–610.
    1. Mills NL, Törnqvist H, Robinson SD, et al. Diesel exhaust inhalation causes vascular dysfunction and impaired endogenous fibrinolysis. Circulation. 2005;112(25):3930–3936.
    1. Mills NL, Törnqvist H, Gonzalez MC, et al. Ischemic and thrombotic effects of dilute diesel-exhaust inhalation in men with coronary heart disease. The New England Journal of Medicine. 2007;357(11):1075–1082.
    1. Teng THK, Williams TA, Bremner A, et al. A systematic review of air pollution and incidence of out-of-hospital cardiac arrest. Journal of Epidemiology and Community Health. 2014;68:37–43.
    1. Swiston JR, Davidson W, Attridge S, Li GT, Brauer M, van Eeden SF. Wood smoke exposure induces a pulmonary and systemic inflammatory response in firefighters. European Respiratory Journal. 2008;32(1):129–138.
    1. Soteriades ES, Smith DL, Tsismenakis AJ, Baur DM, Kales SN. Cardiovascular disease in US firefighters: a systematic review. Cardiology in Review. 2011;19(4):202–215.
    1. Theofilogiannakos EK, Anogeianaki A, Tsekoura P, et al. Arrhythmogenesis in patients with stable chronic obstructive pulmonary disease. Journal of Cardiovascular Medicine. 2008;9(1):89–93.
    1. Vaseghi M, Shivkumar K. The role of the autonomic nervous system in sudden cardiac death. Progress in Cardiovascular Diseases. 2008;50(6):404–419.
    1. Heindl S, Lehnert M, Criée C-P, Hasenfuss G, Andreas S. Marked sympathetic activation in patients with chronic respiratory failure. American Journal of Respiratory and Critical Care Medicine. 2001;164(4):597–601.
    1. Maekura R, Hiraga T, Miki K, et al. Difference in the physiological response to exercise in patients with distinct severity of COPD pathology. Respiratory Care. 2013
    1. Corbo GM, Inchingolo R, Sgueglia GA, Lanza G, Valente S. C-reactive protein, lung hyperinflation and heart rate variability in chronic obstructive pulmonary disease—a pilot study. Journal of Chronic Obstructive Pulmonary Disease. 2013;10(2):200–207.
    1. Zaghla H, Al Atroush H, Samir A, Kamal M. Arrhythmias in patients with chronic obstructive pulmonary disease. Egyptian Journal of Chest Diseases and Tuberculosis. 2013;62(3):377–385.
    1. Tükek T, Yildiz P, Atilgan D, et al. Effect of diurnal variability of heart rate on development of arrhythmia in patients with chronic obstructive pulmonary disease. International Journal of Cardiology. 2003;88(2-3):199–206.
    1. Lazovic B, Mazic S, Stajic Z, Djelic M, Zlatkovic-Svenda M, Putnikovic B. United in prevention- electrocardiographic screening for chronic obstructive pulmonary disease. Acta Informatica Medica. 2013;21(2):127–128.
    1. Baljepally R, Spodick DH. Electrocardiographic screening for emphysema: the frontal plane P axis. Clinical Cardiology. 1999;22(3):226–228.
    1. Chhabra L, Sareen P, Perli D, Srinivasan I, Spodick DH. Vertical p-wave axis: the electrocardiographic synonym for pulmonary emphysema and its severity. Indian Heart Journal. 2012;64(1):40–42.
    1. Warnier MJ, Rutten FH, Numans ME, et al. Electrocardiographic characteristics of patients with chronic obstructive pulmonary disease. Journal of Chronic Obstructive Pulmonary Disease. 2013;10(1):62–71.
    1. Vanfleteren LEGW, Franssen FME, Uszko-Lencer NHMK, et al. Frequency and relevance of ischemic electrocardiographic findings in patients with chronic obstructive pulmonary disease. The American Journal of Cardiology. 2011;108(11):1669–1674.
    1. Holtzman D, Aronow WS, Mellana WM, et al. Electrocardiographic abnormalities in patients with severe versus mild or moderate chronic obstructive pulmonary disease followed in an academic outpatient pulmonary clinic. Annals of Noninvasive Electrocardiology. 2011;16(1):30–32.
    1. Bhatt SP, Nanda S, Kintzer JS. Arrhythmias as trigger for acute exacerbations of chronic obstructive pulmonary disease. Respiratory Medicine. 2012;106(8):1134–1138.
    1. Caglar IM, Dasli T, Turhan Caglar FN, Teber MK, Ugurlucan M, Ozmen G. Evaluation of atrial conduction features with tissue doppler imaging in patients with chronic obstructive pulmonary disease. Clinical Research in Cardiology. 2012;101(8):599–606.
    1. Tükek T, Yildiz P, Akkaya V, et al. Factors associated with the development of atrial fibrillation in COPD patients: the role of P-wave dispersion. Annals of Noninvasive Electrocardiology. 2002;7(3):222–227.
    1. Asad N, Johnson VMP, Spodick DH. Acute right atrial strain: regression in normal as well as abnormal P-wave amplitudes with treatment of obstructive pulmonary disease. Chest. 2003;124(2):560–564.
    1. Abroug F, Ouanes-Besbes L. Detection of acute heart failure in chronic obstructive pulmonary disease patients: role of B-type natriuretic peptide. Current Opinion in Critical Care. 2008;14(3):340–347.
    1. Mueller C, Laule-Kilian K, Frana B, et al. Use of B-type natriuretic peptide in the management of acute dyspnea in patients with pulmonary disease. American Heart Journal. 2006;151(2):471–477.
    1. Wang QP, Cao XZ, Wang XD, et al. Utility of NT-proBNP for identifying LV failure in patients with acute exacerbation of chronic bronchitis. PLOS ONE. 2013;8(1)e52553
    1. Abroug F, Ouanes-Besbes L, Nciri N, et al. Association of left-heart dysfunction with severe exacerbation of chronic obstructive pulmonary disease: diagnostic performance of cardiac biomarkers. American Journal of Respiratory and Critical Care Medicine. 2006;174(9):990–996.
    1. Hoiseth AD, Omland T, Hagve TA, Brekke PH, Soyseth V. NT-proBNP independently predicts long term mortality after acute exacerbation of COPD—a prospective cohort study. Respiratory Research. 2012;13, article 97
    1. Rutten FH, Cramer M-JM, Zuithoff NPA, et al. Comparison of B-type natriuretic peptide assays for identifying heart failure in stable elderly patients with a clinical diagnosis of chronic obstructive pulmonary disease. European Journal of Heart Failure. 2007;9(6-7):651–659.
    1. Inoue Y, Kawayama T, Iwanaga T, Aizawa H. High plasma brain natriuretic peptide levels in stable COPD without pulmonary hypertension or cor pulmonale. Internal Medicine. 2009;48(7):503–512.
    1. Lee MHS, Chang CL, Davies AR, Davis M, Hancox RJ. Cardiac dysfunction and N-terminal pro-B-type natriuretic peptide in exacerbations of chronic obstructive pulmonary disease. Internal Medicine Journal. 2013;43(5):595–598.
    1. Neukamm AMC, Høiseth AD, Hagve TA, Søyseth V, Omland T. High-sensitivity cardiac troponin T levels are increased in stable COPD. Heart. 2013;99(6):382–387.
    1. Soyseth V, Bhatnagar R, Holmedahl NH, et al. Acute exacerbation of COPD is associated with fourfold elevation of cardiac troponin T. Heart. 2013;99(2):122–126.
    1. Odigie-Okon E, Jordan B, Dijeh S, et al. Cardiac injury in patients with COPD presenting with dyspnea: a pilot study. International Journal of Chronic Obstructive Pulmonary Disease. 2010;5:395–399.
    1. Brekke PH, Omland T, Holmedal SH, Smith P, Søyseth V. Troponin T elevation and long-term mortality after chronic obstructive pulmonary disease exacerbation. European Respiratory Journal. 2008;31(3):563–570.
    1. Høiseth AD, Neukamm A, Karlsson BD, Omland T, Brekke PH, Søyseth V. Elevated high-sensitivity cardiac troponin T is associated with increased mortality after acute exacerbation of chronic obstructive pulmonary disease. Thorax. 2011;66(9):775–781.
    1. Parker H, Brenya R, Zarich S, Manthous CA. β-agonists for patients with chronic obstructive pulmonary disease and heart disease? The American Journal of Emergency Medicine. 2008;26(1):104–105.
    1. Høiseth AD, Omland T, Hagve T-A, Brekke PH, Søyseth V. Determinants of high-sensitivity cardiac troponin T during acute exacerbation of chronic obstructive pulmonary disease: a prospective cohort study. BMC Pulmonary Medicine. 2012;12, article 22
    1. Baillard C, Boussarsar M, Fosse J-P, et al. Cardiac troponin I in patients with severe exacerbation of chronic obstructive pulmonary disease. Intensive Care Medicine. 2003;29(4):584–589.
    1. Brekke PH, Omland T, Holmedal SH, Smith P, Søyseth V. Determinants of cardiac troponin T elevation in COPD exacerbation—a cross-sectional study. BMC Pulmonary Medicine. 2009;9(1, article 35)
    1. Chang CL, Robinson SC, Mills GD, et al. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax. 2011;66(9):764–768.
    1. Cook S, Togni M, Schaub MC, Wenaweser P, Hess OM. High heart rate: a cardiovascular risk factor? European Heart Journal. 2006;27(20):2387–2393.
    1. Anthonisen NR, Connett JE, Enright PL, Manfreda J. Hospitalizations and mortality in the lung health study. American Journal of Respiratory and Critical Care Medicine. 2002;166(3):333–339.
    1. Sestini P, Renzoni E, Robinson S, Poole P, Ram FS. Short-acting beta 2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews. 2002;(4)CD001495
    1. Appleton S, Jones T, Poole P, et al. Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews. 2006;(2)CD001387
    1. Bouvy ML, Heerdink ER, De Bruin ML, Herings RMC, Leufkens HGM, Hoes AW. Use of sympathomimetic drugs leads to increased risk of hospitalization for arrhythmias in patients with congestive heart failure. Archives of Internal Medicine. 2000;160(16):2477–2480.
    1. Rossinen J, Partanen J, Stenius-Aarniala B, Nieminen MS. Salbutamol inhalation has no effect on myocardial ischaemia, arrhythmias and heart-rate variability in patients with coronary artery disease plus asthma or chronic obstructive pulmonary disease. Journal of Internal Medicine. 1998;243(5):361–366.
    1. Wang M-T, Tsai C-L, Lo Y-W, Liou J-T, Lee W-J, Lai I-C. Risk of stroke associated with inhaled ipratropium bromide in chronic obstructive pulmonary disease: a population-based nested case-control study. International Journal of Cardiology. 2012;158(2):279–284.
    1. De Vries F, Pouwels S, Bracke M, et al. Use of β2 agonists and risk of acute myocardial infarction in patients with hypertension. British Journal of Clinical Pharmacology. 2008;65(4):580–586.
    1. Chandra D, Stamm JA, Taylor B, et al. Outcomes of noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease in the United States, 1998–2008. American Journal of Respiratory and Critical Care Medicine. 2012;185(2):152–159.
    1. Ameen A, Zedan M, El Shamly M. Comparison between continuous positive airway pressure and bilevel positive pressure ventilation in treatment of acute exacerbation of chronic obstructive pulmonary disease. Egyptian Journal of Chest Diseases and Tuberculosis. 2012;61(3):95–101.
    1. Pladeck T, Hader C, Von Orde A, Rasche K, Wiechmann HW. Non-invasive ventilation: comparison of effectiveness, safety, and management in acute heart failure syndromes and acute exacerbations of chronic obstructive pulmonary disease. Journal of Physiology and Pharmacology. 2007;58(supplement 5, part 2):539–549.
    1. Mariani J, Macchia A, Belziti C, et al. Noninvasive ventilation in acute cardiogenic pulmonary edema: a meta-analysis of randomized controlled trials. Journal of Cardiac Failure. 2011;17(10):850–859.
    1. Mehta S, Jay GD, Woolard RH, et al. Randomized, prospective trial of bilevel versus continuous positive airway pressure in acute pulmonary edema. Critical Care Medicine. 1997;25(4):620–628.
    1. Sin DD, Wong E, Mayers I, et al. Effects of nocturnal noninvasive mechanical ventilation on heart rate variability of patients with advanced COPD. Chest. 2007;131(1):156–163.
    1. Held M, Walthelm J, Baron S, Roth C, Jany B. Functional impact of pulmonary hypertension due to hypoventilation and changes under NIPPV. European Respiratory Journal. 2014;43(1):156–165.
    1. Lukácsovits J, Carlucci A, Hill N, et al. Physiological changes during low- and high-intensity noninvasive ventilation. European Respiratory Journal. 2012;39(4):869–875.
    1. Clague HW, Ahmad D, Carruthers SG. Influence of cardioselectivity and respiratory disease on pulmonary responsiveness to beta-blockade. European Journal of Clinical Pharmacology. 1984;27(5):517–523.
    1. van der Woude HJ, Zaagsma J, Postma DS, Winter TH, van Hulst M, Aalbers R. Detrimental effects of β-blockers in COPD: a concern for nonselective β-blockers. Chest. 2005;127(3):818–824.
    1. Andrikopoulos G, Pastromas S, Kartalis A, et al. Inadequate heart rate control is associated with worse quality of life in patients with coronary artery disease and chronic obstructive pulmonary disease. The RYTHMOS study. Hellenic Journal of Cardiology. 2012;53(2):118–126.
    1. Short PM, Lipworth SIW, Elder DHJ, Schembri S, Lipworth BJ. Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. British Medical Journal. 2011;342, article d2549
    1. Rutten FH, Zuithoff NPA, Hak E, Grobbee DE, Hoes AW. β-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Archives of Internal Medicine. 2010;170(10):880–887.
    1. Cochrane B, Quinn S, Walters H, Young I. Investigating the adverse respiratory effects of beta-blocker treatment: six years of prospective longitudinal data in a cohort with cardiac disease. Internal Medicine Journal. 2012;42(7):786–793.
    1. Etminan M, Jafari S, Carleton B, FitzGerald JM. Beta-blocker use and COPD mortality: a systematic review and meta-analysis. BMC Pulmonary Medicine. 2012;12, article 48
    1. van Gestel YRBM, Hoeks SE, Sin DD, et al. Impact of cardioselective β-blockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis. American Journal of Respiratory and Critical Care Medicine. 2008;178(7):695–700.
    1. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews. 2005;(4)CD003566
    1. Ni Y, Shi G, Wan H. Use of cardioselective beta-blockers in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized, placebo-controlled, blinded trials. Journal of Internal Medicine Research. 2012;40(6):2051–2065.
    1. Lainscak M, Podbregar M, Kovacic D, Rozman J, von Haehling S. Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial. Respiratory Medicine. 2011;105(1):S44–S49.
    1. Jabbour A, Macdonald PS, Keogh AM, et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease. A randomized crossover trial. Journal of the American College of Cardiology. 2010;55(17):1780–1787.
    1. Hawkins NM, Petrie MC, Macdonald MR, et al. Heart failure and chronic obstructive pulmonary disease: the quandary of beta-blockers and beta-agonists. Journal of the American College of Cardiology. 2011;57(21):2137–2138.
    1. Antoniu SA. Reducing mortality for chronic obstructive pulmonary disease: role of statins and angiotensin-converting enzyme inhibitors. Expert Review of Pharmacoeconomics and Outcomes Research. 2009;9(6):523–525.
    1. Mortensen EM, Copeland LA, Pugh MJV, et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respiratory Research. 2009;10, article 45
    1. Mancini GBJ, Etminan M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. Journal of the American College of Cardiology. 2006;47(12):2554–2560.
    1. Kanazawa H, Otsuka T, Hirata K, Yoshikawa J. Association between the angiotensin-converting enzyme gene polymorphisms and tissue oxygenation during exercise in patients with COPD. Chest. 2002;121(3):697–701.
    1. Kanazawa H, Hirata K, Yoshikawa J. Effects of captopril administration on pulmonary haemodynamics and tissue oxygenation during exercise in ACE gene subtypes in patients with COPD: a preliminary study. Thorax. 2003;58(7):629–631.
    1. Zhang X, Wang C, Dai H, Lin Y, Zhang J. Association between angiotensin-converting enzyme gene polymorphisms and exercise performance in patients with COPD. Respirology. 2008;13(5):683–688.
    1. Di Marco F, Guazzi M, Vicenzi M, et al. Effect of enalapril on exercise cardiopulmonary performance in chronic obstructive pulmonary disease: a pilot study. Pulmonary Pharmacology and Therapeutics. 2010;23(3):159–164.
    1. Martin G, Duez H, Blanquart C, et al. Statin-induced inhibition of the rho-signaling pathway activates PPARα and induces HDL apoA-I. Journal of Clinical Investigation. 2001;107(11):1423–1432.
    1. Delerive P, Gervois P, Fruchart J-C, Staels B. Induction of IκBα expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-α activators. Journal of Biological Chemistry. 2000;275(47):36703–36707.
    1. Adam O, Laufs U. Antioxidative effects of statins. Archives of Toxicology. 2008;82(12):885–892.
    1. Zhou Q, Liao JK. Pleiotropic effects of statins—basic research and clinical perspectives. Circulation Journal. 2010;74(5):818–826.
    1. Laufs U, Liao JK. Isoprenoid metabolism and the pleiotropic effects of statins. Current Atherosclerosis Reports. 2003;5(5):372–378.
    1. Lee T-M, Lin M-S, Chang N-C. Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin. The American Journal of Cardiology. 2008;101(4):530–535.
    1. Bartziokas K, Papaioannou AI, Minas M, et al. Statins and outcome after hospitalization for COPD exacerbation: a prospective study. Pulmonary Pharmacology and Therapeutics. 2011;24(5):625–631.
    1. Dobler CC, Wong KK, Marks GB. Associations between statins and COPD: a systematic review. BMC Pulmonary Medicine. 2009;9, article 32
    1. Frost FJ, Petersen H, Tollestrup K, Skipper B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest. 2007;131(4):1006–1012.
    1. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. The New England Journal of Medicine. 2004;350(26):2645–2653.
    1. Van Eeden SF, Sin DD. Chronic obstructive pulmonary disease: a chronic systemic inflammatory disease. Respiration. 2008;75(2):224–238.
    1. Tamagawa E, Suda K, Wei Y, et al. Endotoxin-induced translocation of interleukin-6 from lungs to the systemic circulation. Innate Immunity. 2009;15(4):251–258.
    1. Kido T, Tamagawa E, Bai N, et al. Particulate matter induces translocation of IL-6 from the lung to the systemic circulation. American Journal of Respiratory Cell and Molecular Biology. 2011;44(2):197–204.
    1. Miyata R, Bai N, Vincent R, Sin DD, Van Eeden SF. Statins reduce ambient particulate matter-induced lung inflammation by promoting the clearance of particulate matter <10 μm from lung tissues. Chest. 2013;143(2):452–460.
    1. Miyata R, Hiraiwa K, Cheng JC, et al. Statins attenuate the development of atherosclerosis and endothelial dysfunction induced by exposure to urban particulate matter (PM10) Toxicology and Applied Pharmacology. 2013;272(1):1–11.
    1. Miyata R, Bai N, Vincent R, Sin DD, Van Eeden SF. Novel properties of statins: suppression of the systemic and bone marrow responses induced by exposure to ambient particulate matter (PM(10)) air pollution. American Journal of Physiology: Lung Cellular and Molecular Physiology. 2012;303(6):492–499.

Source: PubMed

3
구독하다